Search Results: spinraza
Summer 2017 Update to SMA Drug Pipeline is Released
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 19 active programs, including one approved therapy. 14 pharmaceutical partners. 5 […]
Cure SMA Funded Standard of Care Paper Published in Neuromuscular Disorders Journal
The journal Neuromuscular Disorders has published a paper reporting on the findings of an international workgroup convened to update the Standard of Care (SOC) for […]
The 2017 Annual SMA Conference is Here!
The 2017 Annual SMA Conference, now in its 29th year, is set to kick off on June 29 and continue into a weekend full of […]
Cure SMA Awards $140,000 Grant to Alberto Kornblihtt, PhD, Universidad de Buenos Aires, Argentina
Cure SMA and FAME (Families of SMA, Argentina) have awarded a $140,000 research grant to Alberto Kornblihtt, PhD, at the Universidad de Buenos Aires, Argentina, […]
RUSP Nomination for SMA Accepted into Evidence Review
The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) announced that they have accepted spinal muscular atrophy into the review process for […]
Cure SMA Welcomes Back Biogen as a National Premier Partner for 2017
Cure SMA is thrilled to welcome Biogen back as a National Premier Partner for 2017. The National Premier Partnership represents the highest level of support […]
Cure SMA Awards $75,000 Grant to Yong-Chao Ma, PhD, Ann & Robert H. Lurie Children’s Hospital of Chicago
Cure SMA has awarded a $75,000 research grant to Yong-Chao Ma, PhD, Ann & Robert H. Lurie Children’s Hospital of Chicago, for his project, “Regulation […]
Cure SMA Awards $75,000 Grant to Stephen J. Kolb, PhD, Ohio State University
Cure SMA has awarded a $75,000 research grant Stephen J. Kolb at Ohio State University, for his project, “Arrested Development or Neurodegeneration? An approach to […]
Biogen Releases New Data from Cherish and Nurture Trials
Biogen will present Phase 3 end of study SPINRAZA® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor […]
SMA Community’s Voice Heard “Loud and Clear” at Last Week’s Patient Focused Drug Development Meeting with the FDA
On April 18, 2017, the SMA community—families, clinicians, researchers, industry and regulators—gathered for a Patient-Focused Drug Development (PFDD) Meeting with the FDA. As part of […]